These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32441114)

  • 1. Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial.
    Wise RA; Anderson JA; Amarenco P; Cowans NJ; Crim C; Denvir MA; Gomez CR; Jones MP; Morris A; Niewoehner D; Yates JC
    Clin Trials; 2020 Aug; 17(4):430-436. PubMed ID: 32441114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Held C; White HD; Stewart RAH; Davies R; Sampson S; Chiswell K; Silverstein A; Lopes RD; Heldestad U; Budaj A; Mahaffey KW; Wallentin L;
    Am Heart J; 2019 Feb; 208():65-73. PubMed ID: 30572273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial.
    Crim C; Anderson JA; Calverley PMA; Celli BR; Cowans NJ; Martinez FJ; Newby DE; Vestbo J; Yates JC; Brook RD
    Am J Respir Crit Care Med; 2020 May; 201(10):1307-1310. PubMed ID: 32017597
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
    Brook RD; Anderson JA; Calverley PM; Celli BR; Crim C; Denvir MA; Magder S; Martinez FJ; Rajagopalan S; Vestbo J; Yates J; Newby DE;
    Heart; 2017 Oct; 103(19):1536-1542. PubMed ID: 28416587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endpoint adjudication in cardiovascular clinical trials.
    Khan MS; Usman MS; Van Spall HGC; Greene SJ; Baqal O; Felker GM; Bhatt DL; Januzzi JL; Butler J
    Eur Heart J; 2023 Dec; 44(46):4835-4846. PubMed ID: 37935635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ; Neffen H
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations.
    McGarvey LP; Magder S; Burkhart D; Kesten S; Liu D; Manuel RC; Niewoehner DE
    Respir Med; 2012 Apr; 106(4):515-21. PubMed ID: 22100536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hybrid automated event adjudication system for clinical trials.
    Yuan F; Bosch J; Eikelboom J; Dagenais GR; Connolly S; Belanger J; Marsden T; Tang C; Swaminathan B; Renters M; Dyal L; Bangdiwala SI
    Clin Trials; 2023 Apr; 20(2):166-175. PubMed ID: 36734212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.
    Kittle J; Lopes RD; Huang M; Marquess ML; Wilson MD; Ascher J; Krishen A; Hasselblad V; Kolls BJ; Roe MT; McGuire DK; Russell SD; Mahaffey KW
    Clin Cardiol; 2017 Oct; 40(10):899-906. PubMed ID: 28605035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
    Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
    Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
    Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
    Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
    Easton JD; Denison H; Evans SR; Knutsson M; Amarenco P; Albers GW; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC;
    Int J Stroke; 2019 Dec; 14(9):908-914. PubMed ID: 31092152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee.
    McGarvey LP; John M; Anderson JA; Zvarich M; Wise RA;
    Thorax; 2007 May; 62(5):411-5. PubMed ID: 17311843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
    Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.